리툭시맙 (Korean Wikipedia)

Analysis of information sources in references of the Wikipedia article "리툭시맙" in Korean language version.

refsWebsite

Global rank Korean rank

35nih.gov

4^th place

33doi.org

2^nd place

3^rd place

9web.archive.org

1^st place

8semanticscholar.org

11^th place

310^th place

6archive.org

6^th place

18^th place

5fda.gov

447^th place

433^rd place

2drugs.com

399^th place

141^st place

2medicines.org.uk

3,823^rd place

2,321^st place

1hres.ca

low place

1europa.eu

68^th place

145^th place

1archive.today

14^th place

15^th place

1medscape.com

719^th place

424^th place

1guidetopharmacology.org

low place

6,859^th place

1books.google.com

3^rd place

9^th place

1handle.net

102^nd place

307^th place

1northwestern.edu

2,302^nd place

3,484^th place

1communityoncology.net

low place

1ophthalmologyjournaloftheaao.com

low place

1rochecanada.com

low place

archive.org (Global: 6^th place; Korean: 18^th place)

Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR 외 (June 2004). “Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis”. 《The New England Journal of Medicine》 350 (25): 2572–2581. doi:10.1056/NEJMoa032534. PMID 15201414.
Shanafelt TD, Madueme HL, Wolf RC, Tefferi A (November 2003). “Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome”. 《Mayo Clinic Proceedings》 78 (11): 1340–1346. doi:10.4065/78.11.1340. PMID 14601692.
Ahmed AR, Spigelman Z, Cavacini LA, Posner MR (October 2006). “Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin”. 《The New England Journal of Medicine》 355 (17): 1772–1779. doi:10.1056/nejmoa062930. PMID 17065638.
Rudnicka D, Oszmiana A, Finch DK, Strickland I, Schofield DJ, Lowe DC 외 (June 2013). “Rituximab causes a polarization of B cells that augments its therapeutic function in NK-cell-mediated antibody-dependent cellular cytotoxicity”. 《Blood》 121 (23): 4694–4702. doi:10.1182/blood-2013-02-482570. PMID 23613524.
Binder M, Otto F, Mertelsmann R, Veelken H, Trepel M (September 2006). “The epitope recognized by rituximab”. 《Blood》 108 (6): 1975–1978. doi:10.1182/blood-2006-04-014639. PMID 16705086.
Burton C, Kaczmarski R, Jan-Mohamed R (June 2003). “Interstitial pneumonitis related to rituximab therapy”. 《The New England Journal of Medicine》 348 (26): 2690–1; discussion 2690–1. doi:10.1056/NEJM200306263482619. PMID 12826649.

archive.today (Global: 14^th place; Korean: 15^th place)

“Rituximab Biosimilars Shown to Be Safe and Effective”. 《www.medscape.com》. 2018년 3월 15일에 원본 문서에서 보존된 문서. 2017년 11월 29일에 확인함.

books.google.com (Global: 3^rd place; Korean: 9^th place)

Bosch X, Ramos-Casals M, Khamashta MA (2013). 《Drugs Targeting B-Cells in Autoimmune Diseases》. Springer Science & Business Media. 1–4쪽. ISBN 9783034807067. 2017년 11월 5일에 원본 문서에서 보존된 문서.

communityoncology.net (Global: low place; Korean: low place)

Patel V, Mihatov N, Cooper N, Stasi R, Cunningham-Rundles S, Bussel JB (2007). “Long-term responses seen with rituximab in patients with ITP” (PDF). 《Community Oncology》 4 (2): 107. doi:10.1016/s1548-5315(11)70061-4. 2007년 9월 29일에 원본 문서 (PDF)에서 보존된 문서. 2007년 4월 18일에 확인함.

doi.org (Global: 2^nd place; Korean: 3^rd place)

dx.doi.org

Tandan R, Hehir MK, Waheed W, Howard DB (August 2017). “Rituximab treatment of myasthenia gravis: A systematic review”. 《Muscle & Nerve》 56 (2): 185–196. doi:10.1002/mus.25597. PMID 28164324. S2CID 19504332.
Singer O, McCune WJ (May 2017). “Update on maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis”. 《Current Opinion in Rheumatology》 29 (3): 248–253. doi:10.1097/BOR.0000000000000382. PMID 28306595. S2CID 35805200.
Dojcinov SD, Fend F, Quintanilla-Martinez L (March 2018). “EBV-Positive Lymphoproliferations of B- T- and NK-Cell Derivation in Non-Immunocompromised Hosts”. 《Pathogens》 7 (1): 28. doi:10.3390/pathogens7010028. PMC 5874754. PMID 29518976.
De A, Ansari A, Sharma N, Sarda A (2017). “Shifting Focus in the Therapeutics of Immunobullous Disease”. 《Indian Journal of Dermatology》 62 (3): 282–290. doi:10.4103/ijd.IJD_199_17 (년 이후로 접속 불가 2022-07-31). PMC 5448263. PMID 28584371.
Saini KS, Azim HA, Cocorocchio E, Vanazzi A, Saini ML, Raviele PR 외 (August 2011). “Rituximab in Hodgkin lymphoma: is the target always a hit?”. 《Cancer Treatment Reviews》 37 (5): 385–390. doi:10.1016/j.ctrv.2010.11.005. PMID 21183282.
Eichenauer DA, Engert A (December 2017). “Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique management”. 《Hematology. American Society of Hematology. Education Program》 2017 (1): 324–328. doi:10.1182/asheducation-2017.1.324. PMC 6142570. PMID 29222274.
Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR 외 (June 2004). “Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis”. 《The New England Journal of Medicine》 350 (25): 2572–2581. doi:10.1056/NEJMoa032534. PMID 15201414.
Tak PP, Kalden JR (May 2011). “Advances in rheumatology: new targeted therapeutics”. 《Arthritis Research & Therapy》 13 (Suppl 1): S5. doi:10.1186/1478-6354-13-S1-S5. PMC 3123966. PMID 21624184.
McGinley MP, Moss BP, Cohen JA (January 2017). “Safety of monoclonal antibodies for the treatment of multiple sclerosis”. 《Expert Opinion on Drug Safety》 16 (1): 89–100. doi:10.1080/14740338.2017.1250881. PMID 27756172. S2CID 36762194.
He D, Guo R, Zhang F, Zhang C, Dong S, Zhou H (December 2013). “Rituximab for relapsing-remitting multiple sclerosis”. 《The Cochrane Database of Systematic Reviews》 (12): CD009130. doi:10.1002/14651858.CD009130.pub3. PMID 24310855.
Froissart A, Veyradier A, Hié M, Benhamou Y, Coppo P (November 2015). “Rituximab in autoimmune thrombotic thrombocytopenic purpura: A success story”. 《European Journal of Internal Medicine》 26 (9): 659–665. doi:10.1016/j.ejim.2015.07.021. PMID 26293834.
Braendstrup P, Bjerrum OW, Nielsen OJ, Jensen BA, Clausen NT, Hansen PB 외 (April 2005). “Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura”. 《American Journal of Hematology》 78 (4): 275–280. doi:10.1002/ajh.20276. PMID 15795920. S2CID 42218074.
Patel V, Mihatov N, Cooper N, Stasi R, Cunningham-Rundles S, Bussel JB (2007). “Long-term responses seen with rituximab in patients with ITP” (PDF). 《Community Oncology》 4 (2): 107. doi:10.1016/s1548-5315(11)70061-4. 2007년 9월 29일에 원본 문서 (PDF)에서 보존된 문서. 2007년 4월 18일에 확인함.
Shanafelt TD, Madueme HL, Wolf RC, Tefferi A (November 2003). “Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome”. 《Mayo Clinic Proceedings》 78 (11): 1340–1346. doi:10.4065/78.11.1340. PMID 14601692.
Ahmed AR, Spigelman Z, Cavacini LA, Posner MR (October 2006). “Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin”. 《The New England Journal of Medicine》 355 (17): 1772–1779. doi:10.1056/nejmoa062930. PMID 17065638.
Jacob A, Weinshenker BG, Violich I, McLinskey N, Krupp L, Fox RJ 외 (November 2008). “Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients”. 《Archives of Neurology》 65 (11): 1443–1448. doi:10.1001/archneur.65.11.noc80069. PMID 18779415.
Hart PA, Chari ST (2013년 6월 11일). “Immunomodulators and Rituximab in the Management of Autoimmune Pancreatitis”. 《Pancreapedia》. doi:10.3998/panc.2013.20.
Pranzatelli MR, Tate ED, Travelstead AL, Longee D (January 2005). “Immunologic and clinical responses to rituximab in a child with opsoclonus-myoclonus syndrome”. 《Pediatrics》 115 (1): e115–e119. doi:10.1542/peds.2004-0845. PMID 15601813.
Khosroshahi A, Wallace ZS, Crowe JL, Akamizu T, Azumi A, Carruthers MN 외 (July 2015). “International Consensus Guidance Statement on the Management and Treatment of IgG4-Related Disease”. 《Arthritis & Rheumatology》 67 (7): 1688–1699. doi:10.1002/art.39132. PMID 25809420. S2CID 39750214.
He Y, Shimoda M, Ono Y, Villalobos IB, Mitra A, Konia T 외 (June 2015). “Persistence of Autoreactive IgA-Secreting B Cells Despite Multiple Immunosuppressive Medications Including Rituximab”. 《JAMA Dermatology》 151 (6): 646–650. doi:10.1001/jamadermatol.2015.59. PMID 25901938.
Seyfizadeh N, Seyfizadeh N, Hasenkamp J, Huerta-Yepez S (January 2016). “A molecular perspective on rituximab: A monoclonal antibody for B cell non Hodgkin lymphoma and other affections”. 《Critical Reviews in Oncology/Hematology》 97: 275–290. doi:10.1016/j.critrevonc.2015.09.001. PMID 26443686.
Pavlasova G, Borsky M, Svobodova V, Oppelt J, Cerna K, Novotna J 외 (September 2018). “Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels”. 《Leukemia》 32 (9): 2028–2031. doi:10.1038/s41375-018-0211-0. PMID 30030508.
Rudnicka D, Oszmiana A, Finch DK, Strickland I, Schofield DJ, Lowe DC 외 (June 2013). “Rituximab causes a polarization of B cells that augments its therapeutic function in NK-cell-mediated antibody-dependent cellular cytotoxicity”. 《Blood》 121 (23): 4694–4702. doi:10.1182/blood-2013-02-482570. PMID 23613524.
Shaw T, Quan J, Totoritis MC (November 2003). “B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience”. 《Annals of the Rheumatic Diseases》 62 (Suppl 2): ii55–ii59. doi:10.1136/ard.62.suppl_2.ii55. PMC 1766758. PMID 14532151.
Borsky M, Hrabcakova V, Novotna J, Brychtova Y, Doubek M, Panovska A 외 (December 2021). “Rituximab induces rapid blood repopulation by CLL cells mediated through their release from immune niches and complement exhaustion”. 《Leukemia Research》 111: 106684. doi:10.1016/j.leukres.2021.106684. PMID 34438120.
Binder M, Otto F, Mertelsmann R, Veelken H, Trepel M (September 2006). “The epitope recognized by rituximab”. 《Blood》 108 (6): 1975–1978. doi:10.1182/blood-2006-04-014639. PMID 16705086.
Grammatikos, Alexandros; Donati, Matthew; Johnston, Sarah L.; Gompels, Mark M. (2021년 8월 30일). “Peripheral B Cell Deficiency and Predisposition to Viral Infections: The Paradigm of Immune Deficiencies”. 《Frontiers in Immunology》 12. 731643. doi:10.3389/fimmu.2021.731643.
Molloy ES, Calabrese LH (September 2012). “Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies”. 《Arthritis and Rheumatism》 64 (9): 3043–3051. doi:10.1002/art.34468. PMID 22422012.
Burton C, Kaczmarski R, Jan-Mohamed R (June 2003). “Interstitial pneumonitis related to rituximab therapy”. 《The New England Journal of Medicine》 348 (26): 2690–1; discussion 2690–1. doi:10.1056/NEJM200306263482619. PMID 12826649.
Kriston L, Härter M, Hölzel L (March 2009). “Challenges in reporting meta-analyses of diagnostic accuracy studies”. 《Annals of Internal Medicine》 150 (6): 430. doi:10.7326/0003-4819-150-6-200903170-00025. PMID 19293085.
Oren S, Mandelboim M, Braun-Moscovici Y, Paran D, Ablin J, Litinsky I 외 (July 2008). “Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response”. 《Annals of the Rheumatic Diseases》 67 (7): 937–941. doi:10.1136/ard.2007.077461. PMID 17981914. S2CID 21878513.
Spelman T, Forsberg L, McKay K, Glaser A, Hillert J (June 2022). “Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: A study of the Swedish multiple sclerosis registry”. 《Multiple Sclerosis》 28 (7): 1051–1059. doi:10.1177/13524585211026272. PMID 34212816. S2CID 235710318.
Tolf A, Wiberg A, Müller M, Nazir FH, Pavlovic I, Laurén I 외 (May 2022). “Factors Associated With Serological Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Rituximab”. 《JAMA Network Open》 5 (5): e2211497. doi:10.1001/jamanetworkopen.2022.11497. PMC 9096596. PMID 35544139. S2CID 248695128.

drugs.com (Global: 399^th place; Korean: 141^st place)

“Rituximab Use During Pregnancy”. 《Drugs.com》. 2019년 12월 16일. 2020년 2월 2일에 확인함.
“Rituximab”. The American Society of Health-System Pharmacists. 2016년 3월 27일에 원본 문서에서 보존된 문서. 2016년 12월 8일에 확인함.

europa.eu (Global: 68^th place; Korean: 145^th place)

ema.europa.eu

“MabThera EPAR”. 《European Medicines Agency》. 2021년 9월 8일에 확인함.

fda.gov (Global: 447^th place; Korean: 433^rd place)

“Boxed Warning and new recommendations to decrease risk of hepatitis B reactivation with the immune-suppressing and anti-cancer drugs Arzerra (ofatumumab) and Rituxan (rituximab)”. 《미국 식품의약국 (FDA)》. 2016년 2월 29일. 2020년 2월 2일에 확인함.
“FDA approves rituximab plus chemotherapy for pediatric cancer indicati”. 《U.S. Food and Drug Administration》. 2021년 12월 3일. 2021년 12월 4일에 확인함. 이 문서는 퍼블릭 도메인 출처의 본문을 포함합니다.
“FDA Warns of Safety Concern Regarding Rituxan in New Patient Population” (보도 자료). 《U.S. Food and Drug Administration (FDA)》. 2006년 12월 18일. 2009년 5월 13일에 원본 문서에서 보존된 문서. 2013년 4월 29일에 확인함.
“Rituximab (marketed as Rituxan) Information”. 《U.S. Food and Drug Administration (FDA)》. 2015년 7월 23일. 2009년 11월 15일에 원본 문서에서 보존된 문서. 2009년 11월 15일에 확인함.
“Rituximab, RA and PML” (PDF). 《U.S. Food and Drug Administration (FDA)》. 2008년 9월 16일에 원본 문서 (PDF)에서 보존된 문서. 2008년 9월 14일에 확인함.

guidetopharmacology.org (Global: low place; Korean: 6,859^th place)

“rituximab | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY”. 《www.guidetopharmacology.org》.

handle.net (Global: 102^nd place; Korean: 307^th place)

hdl.handle.net

World Health Organization (2019). 《World Health Organization model list of essential medicines: 21st list 2019》. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

hres.ca (Global: low place; Korean: low place)

hpr-rps.hres.ca

“Summary Basis of Decision (SBD) for Riximyo”. 《Health Canada》. 2014년 10월 23일. 2022년 5월 29일에 확인함.

medicines.org.uk (Global: 3,823^rd place; Korean: 2,321^st place)

“MabThera 100 mg Concentrate for Solution for Infusion - Summary of Product Characteristics (SmPC)”. 《(emc)》. 2021년 3월 13일. 2021년 3월 26일에 확인함.
“MabThera 1400 mg Solution for Subcutaneous Injection - Summary of Product Characteristics (SmPC)”. 《(emc)》. 2021년 3월 13일. 2021년 3월 26일에 확인함.

medscape.com (Global: 719^th place; Korean: 424^th place)

“Rituximab Biosimilars Shown to Be Safe and Effective”. 《www.medscape.com》. 2018년 3월 15일에 원본 문서에서 보존된 문서. 2017년 11월 29일에 확인함.

nih.gov (Global: 4^th place; Korean: 4^th place)

ncbi.nlm.nih.gov

Tandan R, Hehir MK, Waheed W, Howard DB (August 2017). “Rituximab treatment of myasthenia gravis: A systematic review”. 《Muscle & Nerve》 56 (2): 185–196. doi:10.1002/mus.25597. PMID 28164324. S2CID 19504332.
Singer O, McCune WJ (May 2017). “Update on maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis”. 《Current Opinion in Rheumatology》 29 (3): 248–253. doi:10.1097/BOR.0000000000000382. PMID 28306595. S2CID 35805200.
Dojcinov SD, Fend F, Quintanilla-Martinez L (March 2018). “EBV-Positive Lymphoproliferations of B- T- and NK-Cell Derivation in Non-Immunocompromised Hosts”. 《Pathogens》 7 (1): 28. doi:10.3390/pathogens7010028. PMC 5874754. PMID 29518976.
De A, Ansari A, Sharma N, Sarda A (2017). “Shifting Focus in the Therapeutics of Immunobullous Disease”. 《Indian Journal of Dermatology》 62 (3): 282–290. doi:10.4103/ijd.IJD_199_17 (년 이후로 접속 불가 2022-07-31). PMC 5448263. PMID 28584371.
Saini KS, Azim HA, Cocorocchio E, Vanazzi A, Saini ML, Raviele PR 외 (August 2011). “Rituximab in Hodgkin lymphoma: is the target always a hit?”. 《Cancer Treatment Reviews》 37 (5): 385–390. doi:10.1016/j.ctrv.2010.11.005. PMID 21183282.
Eichenauer DA, Engert A (December 2017). “Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique management”. 《Hematology. American Society of Hematology. Education Program》 2017 (1): 324–328. doi:10.1182/asheducation-2017.1.324. PMC 6142570. PMID 29222274.
Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR 외 (June 2004). “Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis”. 《The New England Journal of Medicine》 350 (25): 2572–2581. doi:10.1056/NEJMoa032534. PMID 15201414.
Tak PP, Kalden JR (May 2011). “Advances in rheumatology: new targeted therapeutics”. 《Arthritis Research & Therapy》 13 (Suppl 1): S5. doi:10.1186/1478-6354-13-S1-S5. PMC 3123966. PMID 21624184.
McGinley MP, Moss BP, Cohen JA (January 2017). “Safety of monoclonal antibodies for the treatment of multiple sclerosis”. 《Expert Opinion on Drug Safety》 16 (1): 89–100. doi:10.1080/14740338.2017.1250881. PMID 27756172. S2CID 36762194.
He D, Guo R, Zhang F, Zhang C, Dong S, Zhou H (December 2013). “Rituximab for relapsing-remitting multiple sclerosis”. 《The Cochrane Database of Systematic Reviews》 (12): CD009130. doi:10.1002/14651858.CD009130.pub3. PMID 24310855.
Froissart A, Veyradier A, Hié M, Benhamou Y, Coppo P (November 2015). “Rituximab in autoimmune thrombotic thrombocytopenic purpura: A success story”. 《European Journal of Internal Medicine》 26 (9): 659–665. doi:10.1016/j.ejim.2015.07.021. PMID 26293834.
Braendstrup P, Bjerrum OW, Nielsen OJ, Jensen BA, Clausen NT, Hansen PB 외 (April 2005). “Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura”. 《American Journal of Hematology》 78 (4): 275–280. doi:10.1002/ajh.20276. PMID 15795920. S2CID 42218074.
Shanafelt TD, Madueme HL, Wolf RC, Tefferi A (November 2003). “Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome”. 《Mayo Clinic Proceedings》 78 (11): 1340–1346. doi:10.4065/78.11.1340. PMID 14601692.
Ahmed AR, Spigelman Z, Cavacini LA, Posner MR (October 2006). “Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin”. 《The New England Journal of Medicine》 355 (17): 1772–1779. doi:10.1056/nejmoa062930. PMID 17065638.
Jacob A, Weinshenker BG, Violich I, McLinskey N, Krupp L, Fox RJ 외 (November 2008). “Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients”. 《Archives of Neurology》 65 (11): 1443–1448. doi:10.1001/archneur.65.11.noc80069. PMID 18779415.
Pranzatelli MR, Tate ED, Travelstead AL, Longee D (January 2005). “Immunologic and clinical responses to rituximab in a child with opsoclonus-myoclonus syndrome”. 《Pediatrics》 115 (1): e115–e119. doi:10.1542/peds.2004-0845. PMID 15601813.
Khosroshahi A, Wallace ZS, Crowe JL, Akamizu T, Azumi A, Carruthers MN 외 (July 2015). “International Consensus Guidance Statement on the Management and Treatment of IgG4-Related Disease”. 《Arthritis & Rheumatology》 67 (7): 1688–1699. doi:10.1002/art.39132. PMID 25809420. S2CID 39750214.
He Y, Shimoda M, Ono Y, Villalobos IB, Mitra A, Konia T 외 (June 2015). “Persistence of Autoreactive IgA-Secreting B Cells Despite Multiple Immunosuppressive Medications Including Rituximab”. 《JAMA Dermatology》 151 (6): 646–650. doi:10.1001/jamadermatol.2015.59. PMID 25901938.
Seyfizadeh N, Seyfizadeh N, Hasenkamp J, Huerta-Yepez S (January 2016). “A molecular perspective on rituximab: A monoclonal antibody for B cell non Hodgkin lymphoma and other affections”. 《Critical Reviews in Oncology/Hematology》 97: 275–290. doi:10.1016/j.critrevonc.2015.09.001. PMID 26443686.
Pavlasova G, Borsky M, Svobodova V, Oppelt J, Cerna K, Novotna J 외 (September 2018). “Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels”. 《Leukemia》 32 (9): 2028–2031. doi:10.1038/s41375-018-0211-0. PMID 30030508.
Rudnicka D, Oszmiana A, Finch DK, Strickland I, Schofield DJ, Lowe DC 외 (June 2013). “Rituximab causes a polarization of B cells that augments its therapeutic function in NK-cell-mediated antibody-dependent cellular cytotoxicity”. 《Blood》 121 (23): 4694–4702. doi:10.1182/blood-2013-02-482570. PMID 23613524.
Shaw T, Quan J, Totoritis MC (November 2003). “B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience”. 《Annals of the Rheumatic Diseases》 62 (Suppl 2): ii55–ii59. doi:10.1136/ard.62.suppl_2.ii55. PMC 1766758. PMID 14532151.
Borsky M, Hrabcakova V, Novotna J, Brychtova Y, Doubek M, Panovska A 외 (December 2021). “Rituximab induces rapid blood repopulation by CLL cells mediated through their release from immune niches and complement exhaustion”. 《Leukemia Research》 111: 106684. doi:10.1016/j.leukres.2021.106684. PMID 34438120.
Binder M, Otto F, Mertelsmann R, Veelken H, Trepel M (September 2006). “The epitope recognized by rituximab”. 《Blood》 108 (6): 1975–1978. doi:10.1182/blood-2006-04-014639. PMID 16705086.
Molloy ES, Calabrese LH (September 2012). “Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies”. 《Arthritis and Rheumatism》 64 (9): 3043–3051. doi:10.1002/art.34468. PMID 22422012.
Burton C, Kaczmarski R, Jan-Mohamed R (June 2003). “Interstitial pneumonitis related to rituximab therapy”. 《The New England Journal of Medicine》 348 (26): 2690–1; discussion 2690–1. doi:10.1056/NEJM200306263482619. PMID 12826649.
Kriston L, Härter M, Hölzel L (March 2009). “Challenges in reporting meta-analyses of diagnostic accuracy studies”. 《Annals of Internal Medicine》 150 (6): 430. doi:10.7326/0003-4819-150-6-200903170-00025. PMID 19293085.
Oren S, Mandelboim M, Braun-Moscovici Y, Paran D, Ablin J, Litinsky I 외 (July 2008). “Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response”. 《Annals of the Rheumatic Diseases》 67 (7): 937–941. doi:10.1136/ard.2007.077461. PMID 17981914. S2CID 21878513.
Spelman T, Forsberg L, McKay K, Glaser A, Hillert J (June 2022). “Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: A study of the Swedish multiple sclerosis registry”. 《Multiple Sclerosis》 28 (7): 1051–1059. doi:10.1177/13524585211026272. PMID 34212816. S2CID 235710318.
Tolf A, Wiberg A, Müller M, Nazir FH, Pavlovic I, Laurén I 외 (May 2022). “Factors Associated With Serological Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Rituximab”. 《JAMA Network Open》 5 (5): e2211497. doi:10.1001/jamanetworkopen.2022.11497. PMC 9096596. PMID 35544139. S2CID 248695128.

dailymed.nlm.nih.gov

“Truxima- rituximab-abbs injection solution”. 《DailyMed》. 2021년 3월 26일에 확인함.
“Ruxience- rituximab-pvvr injection solution”. 《DailyMed》. 2021년 3월 26일에 확인함.
“Riabni- rituximab-arrx injection solution”. 《DailyMed》. 2021년 3월 26일에 확인함.
“Rituxan- rituximab injection, solution”. 《DailyMed》. 2019년 11월 6일. 2020년 2월 2일에 확인함.
“Rituxan Hycela- rituximab and hyaluronidase injection, solution”. 《DailyMed》. 2019년 12월 3일. 2020년 2월 2일에 확인함.

northwestern.edu (Global: 2,302^nd place; Korean: 3,484^th place)

Paul M (2009년 5월 20일). “Popular Cancer Drug Linked to Often Fatal 'Brain Eating' Virus”. Northwestern University News and Information. 2010년 5월 29일에 원본 문서에서 보존된 문서. 2009년 5월 22일에 확인함.

ophthalmologyjournaloftheaao.com (Global: low place; Korean: low place)

“Rituximab Treatment of Patients with Severe, Corticosteroid-Resistant Thyroid-Associated Ophthalmopathy”. 2017년 8월 22일에 원본 문서에서 보존된 문서. 2011년 10월 19일에 확인함.

rochecanada.com (Global: low place; Korean: low place)

“Reports of Bowel Obstruction and Perforation with RITUXAN (rituximab)” (PDF). Roche Canada. 2006년 11월 10일. 2014년 3월 27일에 원본 문서 (PDF)에서 보존된 문서.

semanticscholar.org (Global: 11^th place; Korean: 310^th place)

api.semanticscholar.org

Tandan R, Hehir MK, Waheed W, Howard DB (August 2017). “Rituximab treatment of myasthenia gravis: A systematic review”. 《Muscle & Nerve》 56 (2): 185–196. doi:10.1002/mus.25597. PMID 28164324. S2CID 19504332.
Singer O, McCune WJ (May 2017). “Update on maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis”. 《Current Opinion in Rheumatology》 29 (3): 248–253. doi:10.1097/BOR.0000000000000382. PMID 28306595. S2CID 35805200.
McGinley MP, Moss BP, Cohen JA (January 2017). “Safety of monoclonal antibodies for the treatment of multiple sclerosis”. 《Expert Opinion on Drug Safety》 16 (1): 89–100. doi:10.1080/14740338.2017.1250881. PMID 27756172. S2CID 36762194.
Braendstrup P, Bjerrum OW, Nielsen OJ, Jensen BA, Clausen NT, Hansen PB 외 (April 2005). “Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura”. 《American Journal of Hematology》 78 (4): 275–280. doi:10.1002/ajh.20276. PMID 15795920. S2CID 42218074.
Khosroshahi A, Wallace ZS, Crowe JL, Akamizu T, Azumi A, Carruthers MN 외 (July 2015). “International Consensus Guidance Statement on the Management and Treatment of IgG4-Related Disease”. 《Arthritis & Rheumatology》 67 (7): 1688–1699. doi:10.1002/art.39132. PMID 25809420. S2CID 39750214.
Oren S, Mandelboim M, Braun-Moscovici Y, Paran D, Ablin J, Litinsky I 외 (July 2008). “Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response”. 《Annals of the Rheumatic Diseases》 67 (7): 937–941. doi:10.1136/ard.2007.077461. PMID 17981914. S2CID 21878513.
Spelman T, Forsberg L, McKay K, Glaser A, Hillert J (June 2022). “Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: A study of the Swedish multiple sclerosis registry”. 《Multiple Sclerosis》 28 (7): 1051–1059. doi:10.1177/13524585211026272. PMID 34212816. S2CID 235710318.
Tolf A, Wiberg A, Müller M, Nazir FH, Pavlovic I, Laurén I 외 (May 2022). “Factors Associated With Serological Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Rituximab”. 《JAMA Network Open》 5 (5): e2211497. doi:10.1001/jamanetworkopen.2022.11497. PMC 9096596. PMID 35544139. S2CID 248695128.

web.archive.org (Global: 1^st place; Korean: 1^st place)

“Rituximab”. The American Society of Health-System Pharmacists. 2016년 3월 27일에 원본 문서에서 보존된 문서. 2016년 12월 8일에 확인함.
Bosch X, Ramos-Casals M, Khamashta MA (2013). 《Drugs Targeting B-Cells in Autoimmune Diseases》. Springer Science & Business Media. 1–4쪽. ISBN 9783034807067. 2017년 11월 5일에 원본 문서에서 보존된 문서.
Paul M (2009년 5월 20일). “Popular Cancer Drug Linked to Often Fatal 'Brain Eating' Virus”. Northwestern University News and Information. 2010년 5월 29일에 원본 문서에서 보존된 문서. 2009년 5월 22일에 확인함.
“FDA Warns of Safety Concern Regarding Rituxan in New Patient Population” (보도 자료). 《U.S. Food and Drug Administration (FDA)》. 2006년 12월 18일. 2009년 5월 13일에 원본 문서에서 보존된 문서. 2013년 4월 29일에 확인함.
Patel V, Mihatov N, Cooper N, Stasi R, Cunningham-Rundles S, Bussel JB (2007). “Long-term responses seen with rituximab in patients with ITP” (PDF). 《Community Oncology》 4 (2): 107. doi:10.1016/s1548-5315(11)70061-4. 2007년 9월 29일에 원본 문서 (PDF)에서 보존된 문서. 2007년 4월 18일에 확인함.
“Rituximab Treatment of Patients with Severe, Corticosteroid-Resistant Thyroid-Associated Ophthalmopathy”. 2017년 8월 22일에 원본 문서에서 보존된 문서. 2011년 10월 19일에 확인함.
“Reports of Bowel Obstruction and Perforation with RITUXAN (rituximab)” (PDF). Roche Canada. 2006년 11월 10일. 2014년 3월 27일에 원본 문서 (PDF)에서 보존된 문서.
“Rituximab (marketed as Rituxan) Information”. 《U.S. Food and Drug Administration (FDA)》. 2015년 7월 23일. 2009년 11월 15일에 원본 문서에서 보존된 문서. 2009년 11월 15일에 확인함.
“Rituximab, RA and PML” (PDF). 《U.S. Food and Drug Administration (FDA)》. 2008년 9월 16일에 원본 문서 (PDF)에서 보존된 문서. 2008년 9월 14일에 확인함.

리툭시맙 (Korean Wikipedia)

archive.org (Global: 6th place; Korean: 18th place)

archive.today (Global: 14th place; Korean: 15th place)

books.google.com (Global: 3rd place; Korean: 9th place)

communityoncology.net (Global: low place; Korean: low place)

doi.org (Global: 2nd place; Korean: 3rd place)

dx.doi.org

drugs.com (Global: 399th place; Korean: 141st place)

europa.eu (Global: 68th place; Korean: 145th place)

ema.europa.eu

fda.gov (Global: 447th place; Korean: 433rd place)

guidetopharmacology.org (Global: low place; Korean: 6,859th place)

handle.net (Global: 102nd place; Korean: 307th place)

hdl.handle.net

hres.ca (Global: low place; Korean: low place)

hpr-rps.hres.ca

medicines.org.uk (Global: 3,823rd place; Korean: 2,321st place)

medscape.com (Global: 719th place; Korean: 424th place)

nih.gov (Global: 4th place; Korean: 4th place)

ncbi.nlm.nih.gov

dailymed.nlm.nih.gov

northwestern.edu (Global: 2,302nd place; Korean: 3,484th place)

ophthalmologyjournaloftheaao.com (Global: low place; Korean: low place)

rochecanada.com (Global: low place; Korean: low place)

semanticscholar.org (Global: 11th place; Korean: 310th place)

api.semanticscholar.org

web.archive.org (Global: 1st place; Korean: 1st place)

archive.org (Global: 6^th place; Korean: 18^th place)

archive.today (Global: 14^th place; Korean: 15^th place)

books.google.com (Global: 3^rd place; Korean: 9^th place)

doi.org (Global: 2^nd place; Korean: 3^rd place)

drugs.com (Global: 399^th place; Korean: 141^st place)

europa.eu (Global: 68^th place; Korean: 145^th place)

fda.gov (Global: 447^th place; Korean: 433^rd place)

guidetopharmacology.org (Global: low place; Korean: 6,859^th place)

handle.net (Global: 102^nd place; Korean: 307^th place)

medicines.org.uk (Global: 3,823^rd place; Korean: 2,321^st place)

medscape.com (Global: 719^th place; Korean: 424^th place)

nih.gov (Global: 4^th place; Korean: 4^th place)

northwestern.edu (Global: 2,302^nd place; Korean: 3,484^th place)

semanticscholar.org (Global: 11^th place; Korean: 310^th place)

web.archive.org (Global: 1^st place; Korean: 1^st place)